Table 2 Cox regression analysis on randomized untreated patients. Univariate and multivariable interaction analysis on breast cancer-specific survival evaluating various prognostic parameters for relative risk estimation for the untreated patient cohort. Multivariable model adjusted for grade, lymph node status, tumor size, age, ERα and HER2 status, in addition to the progranulin/sortilin scoring combination. HR: hazard ratio, CI: confidence interval, LN: lymph node, ERα: estrogen receptor alpha, HER2: human epidermal growth factor receptor 2
From: Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
Variable | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
Grade | ||||||
I-II | 1 | 1 | ||||
III | 1.741 | 1.210–2.504 | 0.003 | 1.737 | 1.054–2.860 | 0.030 |
LN status | ||||||
LN negative | 1 | 1 | ||||
LN positive | 1.964 | 1.244–3.101 | 0.004 | 2.250 | 1.348–3.758 | 0.002 |
Tumor size | ||||||
Continuous (mm) | 1.014 | 0.997–1.032 | 0.108 | 1.020 | 0.999–1.041 | 0.059 |
Age | ||||||
Continuous (per year) | 0.966 | 0.936–0.997 | 0.033 | 0.968 | 0.934–1.003 | 0.077 |
ERα | ||||||
ERα negative | 1 | 1 | ||||
ERα positive | 0.824 | 0.525–1.294 | 0.401 | 1.259 | 0.678–2.340 | 0.466 |
HER2 | ||||||
HER2 negative | 1 | 1 | ||||
HER2 positive | 1.376 | 0.849–2.230 | 0.195 | 1.152 | 0.648–2.046 | 0.629 |
Progranulin/sortilin combination | ||||||
Mixed | 1 | 1 | ||||
Double high progranulin/sortilin | 1.922 | 1.224–3.017 | 0.005 | 2.188 | 1.317–3.637 | 0.003 |